Literature DB >> 28399645

Prohibitin - At the crossroads of obesity-linked diabetes and cancer.

Suresh Mishra1,2, Bl Grégoire Nyomba1.   

Abstract

The promoter of a gene that is selectively expressed in just a few cell types provides unique opportunities to study: (1) the pleiotropic function of a protein in two different cell types including the cell compartment specific function, and (2) the crosstalk between two cell/tissue types at the systemic level. This is not possible with a ubiquitous or a highly specific gene promoter. The adipocyte protein-2 ( aP2) is one such gene. It is primarily expressed in adipocytes, but also selectively in monocytic macrophages and dendritic cells, among various immune cell types. Thus, the adipocyte protein-2 gene promoter provides an opportunity to simultaneously manipulate adipose and immune functions in a transgenic animal. Prohibitin (PHB) is a pleiotropic protein that has roles in both adipocytes and immune cells. Adipocyte specific functions of prohibitin are mediated through its mitochondrial function, whereas its immune functions are mediated in a phosphorylation-dependent manner. We capitalized on this attribute of prohibitin to explore the crosstalk between adipose and immune functions, and to discern mitochondrial and plasma membrane-associated cell signaling functions of prohibitin, by expressing wild type prohibitin (Mito-Ob) and a phospho-mutant form of prohibitin (m-Mito-Ob) from the protein-2 gene promoter, individually. Both transgenic mice develop obesity in a sex-neutral manner, but develop obesity-related metabolic dysregulation in a male sex-specific manner. Subsequently, the male Mito-Ob mice spontaneously developed type 2 diabetes and liver cancer, whereas the male m-Mito-Ob mice developed lymph node tumors or autoimmune diabetes in a context-dependent manner. This review provides a point of view on the role of prohibitin in mediating sex differences in adipose and immune functions at the systemic level. We discuss the unique attributes of prohibitin and provide a new paradigm in adipose-immune crosstalk mediated through a pleiotropic protein. Impact statement Prohibitin (PHB) is ubiquitously expressed and plays a role in adipocyte-immune cell cross-talk. Both male and female transgenic mice expressing wild-type PHB in adipose tissue and in macrophages are obese, but only males develop diabetes and liver cancer. When the mice express PHB mutated on tyrosine-114 in adipocytes and macrophages, both males and females are still obese, but none develops liver cancer; instead, males develop lymph node tumors. Adipocyte specific functions of PHB are mediated through its mitochondrial function, whereas its immune functions are mediated in a phosphorylation-dependent manner. Thus, PHB appears to be an important molecule linking obesity, diabetes, and cancer. In addition, this link appears to be affected by sex steroids. Therefore, targeting PHB may lead to a better understanding of the pathogenesis of obesity, diabetes and cancer.

Entities:  

Keywords:  Adipocyte; adipose-immune crosstalk; immune cell; mitochondria; pleiotropic protein; sex dimorphic

Mesh:

Substances:

Year:  2017        PMID: 28399645      PMCID: PMC5477999          DOI: 10.1177/1535370217703976

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  74 in total

Review 1.  SeXX matters in immunity.

Authors:  J G Markle; E N Fish
Journal:  Trends Immunol       Date:  2013-11-13       Impact factor: 16.687

2.  Repressor of estrogen receptor activity (REA) is essential for mammary gland morphogenesis and functional activities: studies in conditional knockout mice.

Authors:  Sunghee Park; Yuechao Zhao; Sangyeon Yoon; Jianming Xu; Lan Liao; John Lydon; Franco DeMayo; Bert W O'Malley; Benita S Katzenellenbogen
Journal:  Endocrinology       Date:  2011-08-23       Impact factor: 4.736

3.  Identification of prohibitin as a Chikungunya virus receptor protein.

Authors:  Phitchayapak Wintachai; Nitwara Wikan; Atichat Kuadkitkan; Thitigun Jaimipuk; Sukathida Ubol; Rojjanaporn Pulmanausahakul; Prasert Auewarakul; Watchara Kasinrerk; Wen-Yu Weng; Mingkwan Panyasrivanit; Atchara Paemanee; Suthathip Kittisenachai; Sittiruk Roytrakul; Duncan R Smith
Journal:  J Med Virol       Date:  2012-11       Impact factor: 2.327

4.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

5.  Identification of the cellular prohibitin 1/prohibitin 2 heterodimer as an interaction partner of the C-terminal cytoplasmic domain of the HIV-1 glycoprotein.

Authors:  Vanessa Emerson; Denise Holtkotte; Tanya Pfeiffer; I-Hsuan Wang; Martina Schnölzer; Tore Kempf; Valerie Bosch
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

6.  Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes.

Authors:  Christopher R Lucas; Hector M Cordero-Nieves; Robert S Erbe; Jaclyn W McAlees; Sumeena Bhatia; Richard J Hodes; Kerry S Campbell; Virginia M Sanders
Journal:  J Immunol       Date:  2012-12-12       Impact factor: 5.422

Review 7.  Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.

Authors:  Adilson Guilherme; Joseph V Virbasius; Vishwajeet Puri; Michael P Czech
Journal:  Nat Rev Mol Cell Biol       Date:  2008-05       Impact factor: 94.444

8.  Androgens target prohibitin to regulate proliferation of prostate cancer cells.

Authors:  Simon C Gamble; Michael Odontiadis; Jonathan Waxman; Jules A Westbrook; Michael J Dunn; Robin Wait; Eric W-F Lam; Charlotte L Bevan
Journal:  Oncogene       Date:  2004-04-15       Impact factor: 9.867

9.  Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth.

Authors:  Sheng Wang; Baohua Zhang; Douglas V Faller
Journal:  EMBO J       Date:  2002-06-17       Impact factor: 11.598

10.  Loss of prohibitin induces mitochondrial damages altering β-cell function and survival and is responsible for gradual diabetes development.

Authors:  Sachin Supale; Fabrizio Thorel; Carsten Merkwirth; Asllan Gjinovci; Pedro L Herrera; Luca Scorrano; Paolo Meda; Thomas Langer; Pierre Maechler
Journal:  Diabetes       Date:  2013-07-17       Impact factor: 9.461

View more
  13 in total

Review 1.  Prohibitin: A hypothetical target for sex-based new therapeutics for metabolic and immune diseases.

Authors:  Suresh Mishra; Bl Grégoire Nyomba
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-04

Review 2.  KDEL Receptors: Pathophysiological Functions, Therapeutic Options, and Biotechnological Opportunities.

Authors:  Ilaria Cela; Beatrice Dufrusine; Claudia Rossi; Alberto Luini; Vincenzo De Laurenzi; Luca Federici; Michele Sallese
Journal:  Biomedicines       Date:  2022-05-25

3.  Prohibitin S-Nitrosylation Is Required for the Neuroprotective Effect of Nitric Oxide in Neuronal Cultures.

Authors:  Youyang Qu; Csaba Konrad; Corey Anderson; Liping Qian; Tina Yin; Giovanni Manfredi; Costantino Iadecola; Ping Zhou
Journal:  J Neurosci       Date:  2020-03-09       Impact factor: 6.167

4.  Characterization of increasing stages of invasiveness identifies stromal/cancer cell crosstalk in rat models of mesothelioma.

Authors:  Joëlle S Nader; Jérôme Abadie; Sophie Deshayes; Alice Boissard; Stéphanie Blandin; Christophe Blanquart; Nicolas Boisgerault; Olivier Coqueret; Catherine Guette; Marc Grégoire; Daniel L Pouliquen
Journal:  Oncotarget       Date:  2018-03-27

Review 5.  Vascular targeted nanotherapeutic approach for obesity treatment.

Authors:  Nicole Remaliah Samantha Sibuyi; Mervin Meyer; Martin Opiyo Onani; Amanda Skepu; Abram Madimabe Madiehe
Journal:  Int J Nanomedicine       Date:  2018-11-23

6.  Characterization and functionality of two members of the SPFH protein superfamily, prohibitin 1 and 2 in Leishmania major.

Authors:  Teresa Cruz-Bustos; Ana Karina Ibarrola-Vannucci; Isabel Díaz-Lozano; José Luis Ramírez; A Osuna
Journal:  Parasit Vectors       Date:  2018-12-04       Impact factor: 3.876

Review 7.  Mitochondrial Quality Control Mechanisms and the PHB (Prohibitin) Complex.

Authors:  Blanca Hernando-Rodríguez; Marta Artal-Sanz
Journal:  Cells       Date:  2018-11-29       Impact factor: 6.600

Review 8.  Prohibitin: a prime candidate for a pleiotropic effector that mediates sex differences in obesity, insulin resistance, and metabolic dysregulation.

Authors:  Yang Xin Zi Xu; Geetika Bassi; Suresh Mishra
Journal:  Biol Sex Differ       Date:  2019-05-22       Impact factor: 5.027

Review 9.  Prohibitin: a potential therapeutic target in tyrosine kinase signaling.

Authors:  Sudharsana Rao Ande; Yang Xin Zi Xu; Suresh Mishra
Journal:  Signal Transduct Target Ther       Date:  2017-12-15

10.  Biomarkers of tumor invasiveness in proteomics (Review).

Authors:  Daniel L Pouliquen; Alice Boissard; Olivier Coqueret; Catherine Guette
Journal:  Int J Oncol       Date:  2020-05-28       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.